Literature DB >> 16318994

T regulatory cells in allergen-specific immunotherapy.

Johan Verhagen1, Alison Taylor, Kurt Blaser, Mübeccel Akdis, Cezmi A Akdis.   

Abstract

A dramatic increase in the prevalence of allergy and asthma has occurred during the past few decades. Although the symptoms of many allergic disorders can be suppressed quite effectively by pharmacological interventions, these do not provide a curative solution and therefore involve lifelong use of medication. Allergen-specific immunotherapy (SIT) on the other hand provides a long-lasting effect on the immune response to common environmental antigens, therefore allowing cessation of the therapy after several years. The changes in the immune response brought about by allergen-SIT are slowly being unveiled and explained. Mechanisms underlying allergen-SIT and in particular the role of regulatory T cells will be discussed in this review, based on recent findings and current concepts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16318994     DOI: 10.1080/08830180500371173

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  4 in total

Review 1.  The role of immune tolerance in asthma pathogenesis.

Authors:  Kurt G Tournoy; Sharen Provoost; Chris Van Hove; Guy Joos
Journal:  Curr Allergy Asthma Rep       Date:  2006-09       Impact factor: 4.806

2.  [Adaptive immune response and associated trigger factors in atopic dermatitis].

Authors:  A Heratizadeh; T Werfel; L M Rösner
Journal:  Hautarzt       Date:  2015-02       Impact factor: 0.751

3.  Suppressive effect of CTB glycoprotein (75 kDa) on IL-4 expression in primary-cultured lymphocytes treated with di(2-ethylhexyl) phthalate.

Authors:  Phil-Sun Oh; Kye-Taek Lim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-05-14       Impact factor: 3.000

Review 4.  Critical appraisal of the clinical utility of sublingual immunotherapy in allergy.

Authors:  S Aissa; R Ben Jazia; J Ayachi; C Ben Salem; A Hayouni; A Abdelghani; H Ben Saad; M Boussarsar
Journal:  Contemp Clin Trials Commun       Date:  2016-06-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.